OnKure Therapeutics Inc. (OKUR)
NASDAQ: OKUR
· Real-Time Price · USD
2.89
0.03 (1.05%)
At close: Jun 06, 2025, 3:59 PM
2.88
-0.35%
After-hours: Jun 06, 2025, 04:04 PM EDT
Company Description
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
The company focuses on developing selective inhibitors of histone deacetylases.
Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors.
The company was incorporated in 2011 and is based in Boulder, Colorado.
OnKure Therapeutics Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Dr. Nicholas A. Saccomano Ph.D. |
Contact Details
Address: 6707 Winchester Circle Boulder, Colorado United States | |
| Website | https://onkuretherapeutics.com |
Stock Details
| Ticker Symbol | OKUR |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001637715 |
| CUSIP Number | n/a |
| ISIN Number | US68277Q1058 |
| Employer ID | 47-2309515 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nicholas A. Saccomano Ph.D. | President, Chief Executive Officer & Director |
| Jason A. Leverone CPA | Chief Financial Officer |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
| Roberta Alton | Senior Vice President of Clinical Operations |
| Rogan P. Nunn J.D. | General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2025 | 4 | Filing |
| May 30, 2025 | 4 | Filing |
| May 30, 2025 | 4 | Filing |
| May 30, 2025 | 4 | Filing |
| May 30, 2025 | 4 | Filing |
| May 30, 2025 | 4 | Filing |
| May 30, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| May 29, 2025 | SCHEDULE 13G | Filing |
| May 28, 2025 | 424B3 | Filing |
| May 28, 2025 | 8-K | Current Report |